Psoriasis

>

Latest News

New Genetic Evidence Supports a Causal Link Between Psoriasis and Depression / image credit ©Ольга Тернавская/stock.adobe.com
Genetic Evidence Supports a Causal Link Between Psoriasis and Depression

December 10th 2025

Genetic predisposition to psoriasis appears to raise depression risk, offering insights into shared inflammatory mechanisms and implications for screening.

Topical Roflumilast 0.3% Demonstrates Significant Efficacy Across Psoriasis Severity Measures in Updated Meta-Analysis / Image credit: ©molekuul.be/AdobeStock
Topical Roflumilast 0.3% Demonstrates Significant Efficacy Across Psoriasis Severity Measures in Updated Meta-Analysis

December 8th 2025

FDA Accepts sNDA for Roflumilast Cream 0.3% to Treat Plaque Psoriasis in Children Aged 2 to 5 Years
FDA Accepts sNDA for Roflumilast Cream 0.3% to Treat Plaque Psoriasis in Children Aged 2 to 5 Years

November 17th 2025

FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis: Daily Dose

November 7th 2025

FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis / image credit:©Calin/AdobeStock
FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis

September 30th 2025

More News

Investigational Oral IL-23 Receptor Antagonist Improves Skin Clearance in Psoriasis: Daily Dose / image credit: ©New Africa/AdobeStock

Investigational Oral IL-23 Receptor Antagonist Improves Skin Clearance in Psoriasis: Daily Dose

Sydney Jennings
August 25th 2025

Your daily dose of the clinical news you may have missed.

Investigational Oral IL-23 Receptor Antagonist Icotrokinra Improves Skin Clearance in Psoriasis in Phase 3 Study / image credit Robert Bissonnette, MD, International Eczema Council

Investigational Oral IL-23 Receptor Antagonist Icotrokinra Improves Skin Clearance in Psoriasis in Phase 3 Study

Grace Halsey
August 11th 2025

The oral peptide that selectively targets IL-23 offers a novel approach to quelling the inflammatory process that underlies plaque psoriasis.

Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces / image courtesy of Arcutis

Roflumilast Foam 0.3% Update: Pivotal Phase 3 Trial Outcomes Published in JAMA Dermatology, Arcutis Announces

Grace Halsey
May 8th 2025

Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.

April Issue of Patient Care Digital Edition is Now Live

April Issue of Patient Care Digital Edition is Now Live

Sydney Jennings
March 27th 2025

The April issue covers atopic dermatitis, highlighting primary care’s role in early diagnosis, key updates from recent conferences, and more.

Tildrakizumab Shows Efficacy for Nail Psoriasis in Phase 3b Trial

Tildrakizumab Shows Efficacy for Nail Psoriasis in Phase 3b Trial

Patient Care Editorial Staff
March 7th 2025

The findings highlight the potential of the interleukin-23 inhibitor to address a notoriously difficult-to-treat manifestation of psoriasis.

New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures / image credit ©InfiniteStudio/AdobeStock

New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures

Sydney Jennings
January 20th 2025

Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.

© 2025 MJH Life Sciences

All rights reserved.